Search - tctmd.com

Displaying 21 - 40 of 129

Sort: Relevancy | Date

News Conference News ISET 2023

Advent of Outpatient Endovascular Care Part of a ‘Sea Change’ in Medicine

Caitlin E. Cox

January 26, 2023

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Caitlin E. Cox

January 20, 2023

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

L.A. McKeown

November 18, 2022

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

Presentation TCT 2022

TCT 209: Chocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Patients With Diabetes Mellitus: Results of the Randomized Chocolate Touch Study

Presenter: Sahil Parikh

September 17, 2022

News Daily News

Worse Complications After PVI in Women Highlight Research Gaps

L.A. McKeown

August 16, 2022

News Daily News

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

L.A. McKeown

August 05, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Conference News SCAI 2022

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

L.A. McKeown

May 23, 2022

News Daily News

Routine IVUS in Peripheral Interventions Supported by Small RCT

L.A. McKeown

March 09, 2022

Presentation TCT 2021

Directional Versus Orbital Atherectomy of Femoropopliteal Artery Lesions: Angiographic and Intravascular Ultrasound Outcomes

Presenter: Anvar Babaev

November 06, 2021

Presentation TCT 2021

Determinants of Drug-coated Balloon Failure in Femoropopliteal Intervention. Insights From a Patient-level Pooled Analysis

Presenter: Prakash Krishnan

November 06, 2021

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Conference News ACC 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

L.A. McKeown

May 16, 2021

FDA Says Newer Paclitaxel Data Is ‘Comforting’ but Limited

News Daily News

FDA Says Newer Paclitaxel Data Are ‘Comforting’ but Limited

L.A. McKeown

January 12, 2021

News Conference News VIVA 2020

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

L.A. McKeown

November 09, 2020

Direct Temsirolimus Delivery Shows Promise in BTK: Phase II Study

News Conference News TCT 2020

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Caitlin E. Cox

October 18, 2020

Presentation TCT 2020

Where Are We With the Data on Paclitaxel?

Presenter: Eric Secemsky

October 18, 2020

Presentation TCT 2020

ILLUMENATE: Four-Year Results With a Low-Dose Paclitaxel Drug-Coated Balloon in De Novo And Restenotic Femoropopliteal Lesions

Presenter: Andrew Holden

October 18, 2020

Presentation TCT 2020

TCT 366: Role of Embolic Protection Devices in Reducing Major Adverse Limb Events in Femoropopliteal Arterial Interventions in a Matched Cohort of Patients With Critical Limb Ischemia: Results From the XLPAD Registry.

Presenter: Qais Radaideh

October 14, 2020

Advertisement

Advent of Outpatient Endovascular Care Part of a ‘Sea Change’ in Medicine

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

TCT 209: Chocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Patients With Diabetes Mellitus: Results of the Randomized Chocolate Touch Study

Worse Complications After PVI in Women Highlight Research Gaps

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

Routine IVUS in Peripheral Interventions Supported by Small RCT

Directional Versus Orbital Atherectomy of Femoropopliteal Artery Lesions: Angiographic and Intravascular Ultrasound Outcomes

Determinants of Drug-coated Balloon Failure in Femoropopliteal Intervention. Insights From a Patient-level Pooled Analysis

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

FDA Says Newer Paclitaxel Data Are ‘Comforting’ but Limited

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Where Are We With the Data on Paclitaxel?

ILLUMENATE: Four-Year Results With a Low-Dose Paclitaxel Drug-Coated Balloon in De Novo And Restenotic Femoropopliteal Lesions

TCT 366: Role of Embolic Protection Devices in Reducing Major Adverse Limb Events in Femoropopliteal Arterial Interventions in a Matched Cohort of Patients With Critical Limb Ischemia: Results From the XLPAD Registry.

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content